Print“St. Jude expects the acquisition to add breadth to its line-up of cardiac arrhythmia treatments and what the company says is a $900 million global cardiac ablation catheter market.”
Cardiovascular device maker St. Jude Medical is buying the Swiss medical technology company Endosense for $170 million (159 million CHF) upfront and up to $161 million (150 million CHF) in additional milestone payments.
Endosense’s patent protected sensing technology gives doctors a real-time, objective measure of the force they apply to the heart wall during catheter ablation, a medical procedure used to treat some types of irregular heart rhythm, or heart arrhythmia. If too little force is applied during the procedure, it can be ineffective, requiring additional treatments. If too much force is applied, there is a risk of tissue injury and complications.
St. Jude expects the acquisition to add breadth to its line-up of cardiac arrhythmia treatments and what the company says is a $900 million global cardiac ablation catheter market. “This transaction significantly accelerates our timeline to providing an irrigated ablation catheter that incorporates force sensing in both international and U.S. markets, and has potential future applications across other St. Jude Medical technology platforms as well,” says Frank Callaghan, president of a St. Jude division focused on the procedure.
Endosense’s TactiCath force-sensing catheter tips are already approved in Europe for use in procedures to treat atrial fibrillation and supra ventricular tachycardia ablation. It recently completed a U.S. trial and will submit a pre-market approval application to the U.S. Food and Drug Administration before the end of the year to use the tips for the treatment of intermittent atrial fibrillation.
August 22, 2013
http://www.burrillreport.com/article-st_jude_medical_acquires_endosense_for_up_to_331_million.html
.gif)
